Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

NCT00005942 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Excess Blasts in Transformation

Interventions

DRUG: liposomal daunorubicin citrate
DRUG: semaxanib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)